#GNT Pharma

Alzheimer’s drug used in cognitive dysfunction syndrome clinical trial

September 5, 2018

Ropesalazine, a drug candidate for Alzheimer’s disease (AD), has shown efficacy in a pilot clinical trial conducted for dogs with cognitive dysfunction syndrome (CDS), according to the drug’s manufacturer, South Korea-based GNT Pharma. There currently is no cure for CDS, a progressive neurodegenerative disorder of senior dogs characterized by altered interaction with family, disorientation, sleep/wake cycle changes, increased house soiling, and activity change. It is accompanied by nerve cell death, amyloid …
New on

Join VPN Plus+ today to get access to exclusive content like:
Video: Tips to working with clients who have mental health conditions
We finally learn…what’s in the box!
A new way to go green: mentor a recent graduate
Tech Talk: A look at advanced degrees
Join Now!
COVID-19
One Health approach drives COVID-19 testing partnership
Telemedicine policy challenged by SPCA group
COVID-19 not transferred via pets, reference laboratory says
Veterinary professionals answer the call to arms
Prepare stimulus loan applications ASAP